Evidence map›Paper›PMID 42794973›Full record

ArticleCancers2026

Enzalutamide Plus ADT for the Treatment of mHSPC: Real-World Evidence from a Bulgarian Cohort.

Manoela Manova, Boryana Ivanova, Antoan Rangelov, Mila Petrova, Assen Dudov, Ivsan Chan, Sevil Ahmed, Victor Nenov, Elitsa Varbanova, Todor Georgiev and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manoela ManovaDepartment of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria.ORCID 0000-0002-8749-7974
Boryana IvanovaDepartment of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria.ORCID 0000-0003-2466-9254
Antoan RangelovNational Council on Prices and Reimbursement of Medicinal Products, 1431 Sofia, Bulgaria.ORCID 0000-0002-0163-6479
Mila PetrovaMedical Oncology Clinic, Multiprofile Hospital for Active Treatment (MHAT) Nadezhda, 1330 Sofia, Bulgaria.
Assen DudovMedical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria.
Ivsan ChanMedical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria.
Sevil AhmedMedical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria.
Victor NenovMedical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria.
Elitsa VarbanovaMedical Oncology Clinic, Acibadem City Clinic Mladost (UMHAT), 1784 Sofia, Bulgaria.
Todor GeorgievSqilline Health, 1766 Sofia, Bulgaria.ORCID 0009-0008-6932-0885
Daniel PenchevSqilline Health, 1766 Sofia, Bulgaria.ORCID 0009-0001-9971-9466
Alexandra SavovaDepartment of Organization and Economy of Pharmacy, Faculty of Pharmacy, Medical University, 1000 Sofia, Bulgaria.ORCID 0000-0003-4579-5524

Funding

Medical University-Sofia
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

androgen deprivation therapyandrogen receptor signaling inhibitorARCHESenzalutamidemetastatic hormone-sensitive prostate cancerreal-world

Identifiers

PMID42794973
PMCPMC13604666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.